Top news of the week: 13.12.2022.
Meet the 71 rising-star VCs who shook up the industry in 2022
Insider asked readers and top VCs to name the rising stars of venture capital. These are the up-and-comers in 2022, and the ones to watch in 2023.
Biotech Startup Apogee Therapeutics Collects $169 Million
The company is developing drugs to treat inflammatory and immunological diseases.
Immune drug developer Apogee emerges as first spinout of biotech Paragon
The new biotech launches with $169 million in venture funding and plans to advance its first drug into clinical testing next year.
Vertex invests in a rare disease drug and its developer
The big biotech is paying Entrada Therapeutics $250 million up front to grab rights to an experimental treatment for myotonic dystrophy type 1 in the latest bid to build its pipeline.
Gene therapy approval won, Bluebird takes on next challenge: selling it
The biotech is still waiting to treat its first commercial patient with Zynteglo, but says it has not seen insurers deny coverage for the beta thalassemia drug.
Amgen’s $28 bln deal is a reasonable gamble
Biotechnology deals are always a gamble, and, on the face of it, Amgen’s $28 billion purchase of Horizon Therapeutics looks both risky and pricey. But large pharmaceutical companies can ...
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc
(b) The Company undertakes, if so reasonably requested by Parent to, as promptly as reasonably practicable, provide its written consent to Parent and to the Irish Takeover Panel …
Amgen Acquires Rare Disease Company Horizon Tx for Almost $28 Billion
Amgen is buying rare disease drug-maker Horizon Therapeutics Plc for $27.8 billion in this year’s biggest biotech deal so far.